Ditchcarbon
  • Contact
  1. Organizations
  2. Byondis B.V.
Public Profile
Research Services
NL
updated 8 months ago

Byondis B.V. Sustainability Profile

Company website

Byondis B.V., headquartered in the Netherlands, is a pioneering biopharmaceutical company specialising in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2013, Byondis has rapidly established itself as a key player in the oncology sector, focusing on targeted therapies that enhance the efficacy and safety of cancer treatments. With a strong presence in Europe and expanding operations in the United States, Byondis is committed to advancing its proprietary technologies, including its unique linker and payload systems. The company’s flagship product, a novel ADC, exemplifies its dedication to improving patient outcomes through precision medicine. Byondis has garnered recognition for its scientific advancements and strategic partnerships, positioning itself as a leader in the biopharmaceutical landscape.

DitchCarbon Score

How does Byondis B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

26

Industry Benchmark

Byondis B.V.'s score of 23 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.

36%

Let us know if this data was useful to you

Byondis B.V.'s reported carbon emissions

Byondis B.V., headquartered in the Netherlands, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company has not outlined any documented reduction targets or climate pledges, which suggests a lack of formal commitments to measurable climate action at this time. It is important to note that Byondis B.V. is a current subsidiary and may inherit emissions data and climate initiatives from its parent organisation. However, no specific details regarding such cascaded data or initiatives have been provided. In the context of the industry, companies are increasingly expected to set science-based targets and engage in transparent reporting of their carbon footprints. Byondis B.V. may need to consider establishing clear climate commitments and reduction strategies to align with these industry standards and expectations.

How Carbon Intensive is Byondis B.V.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Byondis B.V.'s primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Byondis B.V.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Byondis B.V. is in NL, which has a very low grid carbon intensity relative to other regions.

Byondis B.V.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Byondis B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Byondis B.V.'s Emissions with Industry Peers

I-Mab Biopharma

CN
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Shandong New Time Pharmaceutical Co., Ltd.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Zai Lab

CN
•
Pharmaceutical Preparation Manufacturing
Updated about 1 hour ago

Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd

CN
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Phanes Therapeutics, Inc.

US
•
Research and development services (73)
Updated 2 months ago

Hisun Pharmaceutical

CN
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy